# Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

> **NCT01826864** · PHASE3 · WITHDRAWN · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Stage IB Melanoma
- Stage IIA Melanoma
- Stage IIB Melanoma
- Stage IIC Melanoma

## Interventions

- **BIOLOGICAL:** sargramostim
- **PROCEDURE:** sentinel lymph node biopsy
- **OTHER:** laboratory biomarker analysis
- **OTHER:** hypertonic saline

## Key facts

- **NCT ID:** NCT01826864
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-08-05
- **Primary completion:** 2017-08-08
- **Final completion:** 2017-08-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participants enrolled
- **Last updated:** 2020-07-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01826864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01826864, "Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01826864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*